Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
พญ.เพชรรัตน์ วิสุทธิเมธีกร
พ.บ., ป. ชั้นสูงสาขาวิสญั ญีวิทยา, วว.(วิสญ
ั ญี)
ภาควิชาวิสญ
ั ญีวิทยา
วิทยาลัยแพทยศาสตร์กรุ งเทพมหานคร
และวชิรพยาบาล
Topic modules
T&S:
Type O red cells are mixed with pt serum Antibody screen
T&C
Type O red cells are mixed with pt serum Antibody screen
Donor red cells are then mixed with the pt’s serum
to determine possible incompatibility
Blood blank practices
3. PLATELETS
**thrombocytopenia or dysfunction platelets in
the presence bleeding
* prophylactic : plt.counts below 10,000-20,000
* prophylactic preoperative : plt.counts below
50,000
*Microvascular bleeding in surgical patient with
platelets < 50,000
*Neuro/ ocular surgery > 75,000
Intraoperative transfusion practices
3. PLATELETS
*Massive transfusion with microvascular
bleeding with platelets < 100,000
2 BVs = 50,000
3. PLATELETS
50 ml: 0.5- 0.6 x 10 9 platelets (some
RBC’s and WBC’s)
4. CRYOPRECIPITATE
1) Autologous transfusion
2) Blood salvage & refusion
3) Normovolemic hemodilution
“Blood is still the best possible thing to
have in our veins” - Woody Allen
Pathophysiology
-Neuroendocrine responses
-Complement Activation
-Coagulation Activation
- Cytokines Effects
• Patient sample
Coagulation screening
• Repeat compatibility test
– Alloimmunization
Recipient produces Ab’s against RBC membrane Ag
Related to future delayed hemolytic reactions and difficulty
crossmatching
@WBC’s!
• Europe: All products leukodepleted
• USA: Initial FDA recommendation now reversed pending
objective data (NOT length of stay for expense)
• Febrile reactions
– Recipient Ab reacts with donor Ag,
stimulates pyrogens (1-2 % transfusions)
– 20 - 30% of platelet transfusions
– Slow transfusion, antipyretic, meperidine for
shivering
• TRALI (Transfusion related acute lung injury)
– Donor Ab reacts with recipient Ag (1/ 10,000)
– noncardiogenic pulmonary edema
– Supportive therapy
Transfusion-related Acute Lung Injury
(TRALI)
Pathophysiology
Leukocyte Ab in donor react with pt. leukocytes
Activate complements
Endothelial damage
Patient at risk
Post-transfusion purpura
– Recipient Ab leads to sudden destruction of platelets
1-2 weeks after transfusion (sudden onset)
– Rare complication
Immunomodulatory effects of transfusion
Hepatitis B
• Risk 1/ 200,000 due to HBsAg, antiHBc screening
(7-17 % of PTH)
• Per unit risk 1/63-66,000
• 0.002% residual HBV remains in ‘negative’ donors
(window 2-16 weeks)
• Anti-HBc testing retained as surrogate marker for
HIV
NANB and Hepatitis C
III. Protozoal
• Trypanosoma cruzi (Chaga’s disease)
• Malaria
• Toxoplasmosis
• Leishmaniasis
Serological Testing
for Infectious markers
• HIV – Ag
• Anti – HIV
• HBsAg
• Anti – HCV
• Test for syphilis
METABOLIC COMPLICATIONS
Citrate toxicity
• Citrate (3G/ unit WB) binds Ca2+ / Mg+
• Metabolized liver, mobilization bone stores
• Hypocalcemia ONLY if > 1 unit/ 5 min or
hepatic dysfunction
• Hypotension more likely due to cardiac
output/ perfusion than calcium (except
neonates)
• Worse with hypothermia/ hepatic dysfunction
Hyperkalemia